What is this study about?
The aim of this study is to develop better biomarkers for diagnosis and treatment of Lewy body disorders. In particular, there is a need to understand how the contribution of co-existing Alzheimer’s disease may affect the diagnosis and clinical course of Lewy body disorders.
What is involved?
This study will recruit a group of individuals with Lewy body disorders causing cognitive impairment or dementia.. Participants will have up to 4-5 visits over 3.5 years. Participants will have a comprehensive neurological evaluation which will include donation of blood, urine, and cerebrospinal fluid samples.
Who can participate?
An individual may be able to take part in the trial if he/she speaks English or Spanish and:
- Has been diagnosed with dementia with Lewy bodies (DLB) OR
- Has been diagnosed with Parkinson’s disease with cognitive change.
The U.S. National Institutes of Health
For more information
Kate Smith (coordinator)
Helen Mejia-Santana MS (coordinator)
Telephone (212) 305-9183